TY - JOUR T1 - Wearable devices can identify Parkinson’s disease up to 7 years before clinical diagnosis JF - medRxiv DO - 10.1101/2022.11.28.22282809 SP - 2022.11.28.22282809 AU - Ann-Kathrin Schalkamp AU - Kathryn J Peall AU - Neil A Harrison AU - Cynthia Sandor Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/12/05/2022.11.28.22282809.abstract N2 - Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder with a long latent phase and no currently existing disease-modifying treatments. Reliable predictive biomarkers that could transform efforts to develop neuroprotective treatments remain to be identified. Using UK Biobank, we investigated the predictive value of accelerometry in identifying prodromal PD in the general population and compared this digital biomarker to models based on genetics, lifestyle, blood biochemistry, and prodromal symptoms data. Machine learning models trained using accelerometry data achieved high test performance in distinguishing both clinically diagnosed PD (AUROC: 0.83±0.03, AUPRC: 0.51±0.06) and prodromal PD up to seven years pre-diagnosis (AUROC: 0.81±0.03, AUPRC: 0.37±0.05) from the general population, and outperformed all other modalities tested. Accelerometry is a potentially important, low-cost screening tool for identifying people at risk of developing PD and identifying subjects for clinical trials of neuroprotective treatments.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work described here is part-funded by the European Regional Development Fund, administered through the Welsh Government. We are also grateful for the Advanced Research Computing at Cardiff.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:ukbiobank.ac.uk/I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the UK Biobank (ukbiobank.ac.uk/) are available on application to the UK Biobank. ER -